N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
The move strengthens GBL’s clinical-stage presence in the United States
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Subscribe To Our Newsletter & Stay Updated
